MiniMed Debuts Next-Gen Diabetes Tech at ADA Scientific Sessions
Event summary
- MiniMed will showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions from June 5-8, 2026.
- The event marks MiniMed's first U.S. diabetes congress as a standalone public company.
- MiniMed will present emerging clinical data on its connected solutions, including the impact of its refreshed sensor portfolio.
- Hands-on demonstrations of the MiniMed Flex™ system and MiniMed Go™ smart insulin pen system will be available.
- MiniMed will host sponsored events, including a product theater and learning byte, featuring discussions with MiniMed and independent speakers.
The big picture
MiniMed's presence at the ADA Scientific Sessions underscores its strategic focus on reducing the daily burden of diabetes through advanced automation and intuitive designs. As a standalone public company, MiniMed is positioning itself to capitalize on the growing demand for innovative diabetes technology. The event highlights the company's commitment to delivering strong clinical outcomes and expanding its product pipeline to meet the needs of people with diabetes globally.
What we're watching
- Product Adoption
- How the hands-on demonstrations of MiniMed Flex™ and MiniMed Go™ will impact early adoption rates and market penetration.
- Clinical Data
- Whether the emerging clinical data presented at the conference will strengthen MiniMed's position in the diabetes technology market.
- Competitive Positioning
- The pace at which MiniMed can differentiate itself from competitors with its next-generation technology and integrated ecosystem.
Related topics